Fibrolamellar hepatocellular carcinoma: current clinical perspectives
Kelly J Lafaro,1 Timothy M Pawlik2 1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcino...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-10-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/fibrolamellar-hepatocellular-carcinoma-current-clinical-perspectives-peer-reviewed-article-JHC |
| _version_ | 1819209211019526144 |
|---|---|
| author | Lafaro KJ Pawlik TM |
| author_facet | Lafaro KJ Pawlik TM |
| author_sort | Lafaro KJ |
| collection | DOAJ |
| description | Kelly J Lafaro,1 Timothy M Pawlik2 1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ~1%–9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10–35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC. Keywords: hepatocellular carcinoma, fibrolamellar, hepatocyte paraffin I, locoregional therapy |
| first_indexed | 2024-12-23T05:51:40Z |
| format | Article |
| id | doaj.art-f7c5083f20a14b7ba3502aed57acd574 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-12-23T05:51:40Z |
| publishDate | 2015-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-f7c5083f20a14b7ba3502aed57acd5742022-12-21T17:57:57ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692015-10-012015Issue 115115724079Fibrolamellar hepatocellular carcinoma: current clinical perspectivesLafaro KJPawlik TMKelly J Lafaro,1 Timothy M Pawlik2 1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ~1%–9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10–35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC. Keywords: hepatocellular carcinoma, fibrolamellar, hepatocyte paraffin I, locoregional therapyhttps://www.dovepress.com/fibrolamellar-hepatocellular-carcinoma-current-clinical-perspectives-peer-reviewed-article-JHCfibrolamellarlivertreatmentupdates |
| spellingShingle | Lafaro KJ Pawlik TM Fibrolamellar hepatocellular carcinoma: current clinical perspectives Journal of Hepatocellular Carcinoma fibrolamellar liver treatment updates |
| title | Fibrolamellar hepatocellular carcinoma: current clinical perspectives |
| title_full | Fibrolamellar hepatocellular carcinoma: current clinical perspectives |
| title_fullStr | Fibrolamellar hepatocellular carcinoma: current clinical perspectives |
| title_full_unstemmed | Fibrolamellar hepatocellular carcinoma: current clinical perspectives |
| title_short | Fibrolamellar hepatocellular carcinoma: current clinical perspectives |
| title_sort | fibrolamellar hepatocellular carcinoma current clinical perspectives |
| topic | fibrolamellar liver treatment updates |
| url | https://www.dovepress.com/fibrolamellar-hepatocellular-carcinoma-current-clinical-perspectives-peer-reviewed-article-JHC |
| work_keys_str_mv | AT lafarokj fibrolamellarhepatocellularcarcinomacurrentclinicalperspectives AT pawliktm fibrolamellarhepatocellularcarcinomacurrentclinicalperspectives |